Uncategorized Archives - Page 13 of 87 - PsychedelicNewsWire (PNW)

ThursdayJan 27, 2022 9:30 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend

Psychedelics pose potential as effective treatments for mental-health issues such as depression, anxiety, and substance abuse Well+Good says psychedelics “poised to change the course of mental health treatment” Cybin working to combine novel psychedelic molecules with controllable drug-delivery systems through proprietary deuterated process A USA Today article is touting psychedelics as the next big thing in mental health treatment (https://ibn.fm/3ZGGE). This forecast aligns perfectly with what Cybin (NEO: CYBN) (NYSE American: CYBN) has been working toward since the company started: a strategic psychedelics to therapeutics model that will transform the mental health space. “If you haven't heard about psychedelics being used as a treatment…

TuesdayJan 25, 2022 12:21 pm

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Reports Findings of Commissioned Study Showing a Majority of Affected Americans Approve of Psychedelics as an Alternative Treatment for Select Mental Conditions

The Harris Poll conducted a survey on behalf of Delic Holdings, polling 2,037 adults ages 18 and older, 953 of whom suffer from anxiety/depression/PTSD The survey revealed that 65% of Americans living with anxiety/depression/PTSD believe that psychedelic medicine should be available to patients with treatment-resistant conditions 66%, 62%, and 56% are open to pursuing ketamine, psilocybin, and MDMA, respectively, to treat anxiety/depression/PTSD if these psychedelic drugs were each proven more effective than prescription medication with fewer side effects Though the U.S. government has not yet federally recognized a medical use for most psychedelic drugs, research by renowned universities and companies…

MondayJan 24, 2022 12:29 pm

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Plans Program to Provide Resources for Safe, Effective Integration of Psychedelic-Assisted Psychotherapies into Existing Medical Practices

Mydecine plans to launch a program to provide products and services to healthcare professionals, clinics, and hospitals in Canada looking to treat patients through psychedelic-assisted psychotherapy The products and services, which will be available for purchase as a package, include cGMP psilocybin and MDMA, therapy manuals, investigative brochures, protocol training, advisory services, and post-therapy support The planned launch follows an amendment to federal regulations allowing physicians to request and prescribe restricted drugs for treatment-resistant patients Canada began the year on a high note by updating the Special Access Program (“SAP”), a move that demonstrates the government’s serious consideration of the…

FridayJan 21, 2022 10:38 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0) Corporate Update Points to Profitability in 2022 and Beyond

In 2021, Delic’s investments and acquisitions allowed for an annualized revenue run-rate of over $9MM Going into the new year, the company looks forward to opening additional ketamine infusion treatment clinics, growing them by 15 within the next 18 months Delic’s growth has been attributed to the strong demand for alternatives to current treatments for mental health conditions Its management is confident that the foundations laid down so far position Delic for growth and profitability in 2022 and beyond 2021 was an excellent year for Delic Holdings (CSE: DELC) (OTCQB: DELCF) (FRA: 6X0), as indicated in the company’s recent update…

WednesdayJan 19, 2022 9:30 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Attended This Year’s H.C. Wainwright Bioconnect Virtual Conference

Delic Holdings Corp is a leader in new medicines and treatments for a modern world, with a business network which includes psychedelic wellness clinics, a licensed psilocybin research lab, a famed psychedelic wellness event, and dedicated media platforms The company announced that its co-founder and CEO, Matt Stang, presented at the H.C. Wainwright Bioconnect Virtual Conference on January 10-13, 2022 Delic Holdings (CSE: DELC) (OTCQB: DELCF), a leader in new medicines and treatments for a modern world, has long been known for its role as a trailblazer in improving access to health benefits across the country and reframing the conversation…

WednesdayJan 19, 2022 9:00 am

Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) CEO Shares Company Success Insights on Bell2Bell Podcast

Mr. Josh Bartch, the CEO, Chairman, and Co-Founder of Mydecine, attributed the company’s success to its phased approach to product research and development He noted significant strides in smoking cessation and PTSD research over the 2021 calendar year, which will be integral to operations in the new year Mr. Bartch was also proud of the current efficacy data around psilocybin to treat nicotine dependance which is significantly better than what is available in the market Going into 2022, Mydecine will embark on more clinical studies on smoking cessation and PTSD, focus more on novel compound production and growing its Mindleap…

WednesdayJan 19, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Emerging as Psychedelics Leader, Looking Forward to ‘Transformative’ Year

Company marked host of major milestones and accomplishments in 2021 Approvals, licenses, expansions and growth all essential pieces of Cybin success CYBN’s innovative operational and R&D pipeline platforms expected to support four first-in-human clinical studies in 2022 As the new year begins, Cybin (NEO: CYBN) (NYSE American: CYBN) couldn’t be in a better position. The biopharmaceutical company’s commitment to establishing a stronghold in the psychedelics space paid off big last year, with the company marking a host of major milestones and accomplishments and looking toward more of the same for 2022. "2021 was an exciting year for Cybin,” said Cybin CEO…

WednesdayJan 12, 2022 9:00 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Notes ‘Milestone’ Step with USPTO Notice of Allowance CYB004

Cybin awarded notice for company’s innovative treatment of anxiety disorders Approval demonstrates company’s dedication to discovery and development of psychedelic-based compounds for addressing mental health Anxiety disorders rank among the most common mental illnesses in the country Cybin (NEO: CYBN) (NYSE American: CYBN) has taken another step forward in its strategic plan to strengthen its position as leading innovator in developing putative psychedelic compounds. The company has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for its patent application for an innovative treatment of anxiety disorders (https://ibn.fm/8hMWh). Cybin announced that it has been awarded a USPTO…

MondayJan 10, 2022 12:21 pm

Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) (FSE: ONFA) Announces Completion of Target-Based Model in Its AI-Driven Drug Discovery Program

The AI-driven drug discovery program uses not only artificial intelligence but also machine learning, which is a relatively new concept and is continuously expanding The use of artificial intelligence in the drug development space may help eliminate or reduce the manual operations that a company typically must undergo to identify and make necessary improvements to drugs The new model will allow the company to rapidly screen billions of structures promoting near term patent filings for novel psychedelic molecules Mydecine has already been able to eliminate unsuccessful candidates early on with the use of this technology Mydecine’s primary focus is the…

MondayJan 10, 2022 12:04 pm

Congressman Calls for Liberalized Access to Psilocybin; Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Positions for Growth Within Psychedelics Sector

Congressman Earl Blumenauer recently wrote to his peers, urging them to petition the DEA to permit terminally ill patients to use psilocybin as part of their treatment Although 41 states permit terminal patients to try investigational drugs, psilocybin continues to be banned by the DEA Change seems to be coming within the sector as evidenced by its decriminalization in cities such as Denver and Oakland Delic Corp has positioned itself as a leading psychedelic wellness platform, with business interests in ketamine infusion clinics, media, event management, and psilocybin research In mid-December, Representative Earl Blumenauer circulated an open letter to his…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized